关键词: 斯鲁利单抗, 注射液, 药物性肺损伤, 间质性肺炎, 药品不良反应

Abstract: Objective To analyze the incidence of lung injury caused by serplulimab injection and related risk factors so as to provide data for clinical use. Methods The clinical data of one case of adverse reactions - interstitial pneumonia - caused by serplulimab injection was analyzed while the related literature was reviewed and summarized. Results One patient was treated with chemotherapy using injectable nedaplatin and etoposide injection in combination with serplulimab injection, who developed interstitial pneumonia during the 2nd course of combined chemotherapy (a total of three courses), which was determined to be due to the serplulimab injection by correlation analysis. The incidence of lung injury caused by serplulimab injection ranged from 1.6% to 8.2% according to literature, and the associated risk factors included history of smoking, history of tobacco exposure, poor health status, age, underlying lung disease and history of lung radiotherapy. This injection was recommended for use in patients under 65. Conclusion Clinicians are to be alert to the risk of interstitial pneumonia attributed to serplulimab injection. Prior to medication, thorough assessment of potential risk factors is crucial, and precautions need to be taken. During medication, respiratory symptoms of the patient should be closely monitored. In case of drug-related lung injury, pulmonary imaging, pulmonary function and arterial blood gas of the patient have to be examined before the severity is assessed to ensure quick interventions and safety of the patient.

Key words: serplulimab, injection, drug-related lung injury, interstitial pneumonia, adverse drug reaction